View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry

Blog

Immuno-Oncology Drug Development: Challenges & Next Steps


  • December 23, 2015

  • Axel Hoos, MD, PhD, GlaxoSmithKline speaking at the Inaugural IO360° Conference

    PharmaTalk Radio’s Valerie Bowling welcomes Immuno-Oncology 360° Co-Chair James Gulley, MD, PhD, National Cancer Institute as he leads a discussion with fellow Co-Chair, Axel Hoos, MD, PhD, GlaxoSmithKline. Together they discuss what’s currently happening in Immuno-Oncology and its impact on how cancer is being treated. They cover the latest challenges and next steps. More specifically they address:

    • – Ipilumumab/Nivo/Pembro challenges
    • – What can we learn from the development of sipuleucel-T that may be applicable for other therapeutic vaccines?
    • – Challenges with the following modalities: Checkpoints, Oncolytic Virus’, Adoptive T-Cells, Cancer Vaccines
    • – Blinitumumab
    • – The more interesting agents in late stage development now in immunotherapy and its promise
    • – Immune related adverse events
    • – Adoptive cellular therapies, what is the most promising?
    • – Will IO become backbone therapies for cancer?
    • – What’s the next set of assets that are going to come out?-
    • – What can we expect within the next year or two?

    Guests:

    James Gulley, MD, PhD
    Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute

    Axel Hoos, MD, PhD, VP, Oncology R&D, GlaxoSmithKline

    Listen to the show here: http://www.blogtalkradio.com/pharmatalk/2015/12/21/immuno-oncology-drug-development-challenges-next-stepshttp://www.blogtalkradio.com/pharmatalk/2015/12/21/immuno-oncology-drug-development-challenges-next-steps

    The Immuno-Oncology 360° conference is scheduled for February 2-3, 2016  at the New York Academy of Medicine in NYC. For more information, please visit www.theconferenceforum.org.